Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study

Multiple Cancer Types

This phase I/II trial tests the safety and efficacy of split-course adaptive radiation therapy in combination with immunotherapy with or without chemotherapy for the treatment of patients with stage IV lung cancer or lung cancer that that has spread to nearby tissue or lymph nodes (locally advanced). Radiation therapy is a standard cancer treatment that uses high energy rays to kill cancer cells and shrink tumors. Split-course adaptive radiation therapy uses patient disease response to alter the intensity of the radiation therapy. Immunotherapy with monoclonal antibodies such as pembrolizumab, ipilimumab or nivolumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs like carboplatin, pemetrexed, and paclitaxel work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving split-course adaptive radiation therapy with standard treatments like immunotherapy and chemotherapy may be more effective at treating stage IV or locally advanced lung cancer than giving them alone.

Disease Sites: Lung, Non Small Cell, Phase I

Phase: I/II

Investigator: Osmundson, Evan

NCTID: NCT05501665

Protocol No: VICCTHOP2185

Learn More

Gabapentin plus Ketamine for the Prevention of Acute and Chronic Pain in Patients with Locally Advanced Head and Neck Cancer Undergoing Chemoradiation

Multiple Cancer Types

This phase I/II trial studies the side effects and best dose of a combination of gabapentin and ketamine and to see how well it works to prevent acute and chronic pain in patients receiving chemotherapy and radiation therapy (chemoradiation) for head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced). Gabapentin is a medication that is commonly used to treat nerve related pain. Specifically, it has been used to treat pain involving the mouth, throat and nasal passages in head and neck cancer patients treated with radiation. Ketamine is a type of general anesthetic that blocks pathways to the brain involved with sensing pain. This trial may help doctors determine how patients tolerate the combination of gabapentin and ketamine and to find the correct dosing for ketamine in those taking gabapentin. This will be the basis for a future, larger study to look at how effective this combination is at reducing and/or preventing pain in head and neck cancer patients.

Disease Sites: Head/Neck, Phase I

Phase: I/II

Investigator: Lockney, Natalie

NCTID: NCT05156060

Protocol No: VICCHNP2173

Learn More

Active Myeloid Target Compound Decitabine and Cedazuridine in Combination with Itacitinib for the Treatment of Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes, ABNL-MARRO Study

This phase I/II trial tests the safety, side effects, and best dose of decitabine and cedazuridine (ASTX727) in combination with itacitinib and how well they work in treating patients with myelodysplastic/ myeloproliferative neoplasm. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine and cedazuridine in combination with itacitinib may work better in treating patients with myelodysplastic/myeloproliferative neoplasm.

Disease Sites: Not Available

Phase: I/II

Investigator: Not Available

NCTID: NCT04061421

Protocol No: VICCHEMP1977

Learn More

A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia

Multiple Cancer Types

This open label ascending dose study is designed to evaluate the safety, pharmacokinetics
(PK), pharmacodynamics (PD), and immunogenicity of AV-380 in metastatic cancer patients with
Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind
circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in
cancer-induced cachexia.

Disease Sites: Colon, Pancreatic, Phase I, Rectal

Phase: I

Investigator: Agarwal, Rajiv

NCTID: NCT05865535

Protocol No: VICC-DTSUP24138P

Learn More

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

The main purpose of this study is to assess the efficacy and safety of volrustomig compared
to observation in participants with unresected locally advanced head and neck squamous cell
carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent
chemoradiotherapy (cCRT).

Disease Sites: Not Available

Phase: III

Investigator: Choe, Jennifer

NCTID: NCT06129864

Protocol No: VICC-DTHAN24071

Learn More